Attempting to levy duties on them. Prices may eventually rise as a result of the tariffs, which may worsen shortages of some medications, especially generic ones.
Trump’s assertion that his most recent initiative would significantly lower prescription costs was refuted by at least one health care policy researcher.
Chris Meekins, a Raymond James analyst, wrote in a note to clients Sunday night, “Trump has a long history in his first term of talking bigger on drug pricing than what his policies would actually do.”
“Trump’s proposed executive actions are less likely to be carried out the more extravagant they are, as successful court challenges will be far more likely.”
Trump has not made as big of a point of cutting medicine prices this term as he did during his first administration.
Additionally, his team informed Politico last year that he had abandoned the “Most Favored Nation” approach, which is vehemently opposed by many Republicans.
